Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CMND | 6-K | neutral | 4/10 | Clearmind Medicine announced completion of dosing for all 24 participants in Part A of its Phase I/II clinical trial for | Jun 16, 2026 |
| ABOS | 8-K | neutral | 4/10 | Acumen Pharmaceuticals announced the nomination of two Enhanced Brain Delivery (EBD) development candidates, ACU301 and | Jun 16, 2026 |
| AVTX | 8-K | bullish | 6/10 | Avalo Therapeutics filed an 8-K announcing the advancement of AVTX-010, a long-acting next-generation anti-IL-1 mAb, wit | Jun 16, 2026 |
| HCWB | 8-K | bullish | 7/10 | HCW Biologics announced positive preliminary human data from the first two dose cohorts of its Phase 1 trial for HCW9302 | Jun 16, 2026 |
| IVVD | PRESS-RELEASE | neutral | 5/10 | Invivyd announced completion of enrollment in its Phase 3 LIBERTY trial comparing VYD2311 (monoclonal antibody) against | Jun 16, 2026 |
| HCWB | PRESS-RELEASE | bullish | 6/10 | HCW Biologics reported positive preliminary Phase 1 data for HCW9302 in alopecia areata: all three patients in the secon | Jun 16, 2026 |
| AVTX | PRESS-RELEASE | bullish | 5/10 | Avalo Therapeutics announced advancement of AVTX-010, a next-generation anti-IL-1β monoclonal antibody, with an IND subm | Jun 16, 2026 |
| PTCT | 8-K | neutral | 5/10 | PTC Therapeutics priced $500M of 0% convertible senior notes due 2031 (plus a $50M greenshoe) to refinance its 1.5% 2026 | Jun 16, 2026 |
| NBP | 6-K | bullish | 5/10 | NovaBridge Biosciences announced FDA Fast Track Designation for givastomig in first-line HER2-negative metastatic gastri | Jun 16, 2026 |
| PBH | 8-K | mixed | 6/10 | Prestige Consumer Healthcare completed its $1.045B acquisition of the Breathe Right brand from Foundation Consumer Brand | Jun 16, 2026 |
| ONMD | CLUSTER | bullish | 6/10 | CEO Aaron Green and director/10% owner Thomas Kosasa made open-market purchases totaling $121K over a 7-day window, repr | Jun 16, 2026 |
| ATHE | 6-K | neutral | 2/10 | Analysis based on filing metadata only, document content was unavailable. Alterity Therapeutics filed a Form 6-K furnish | Jun 16, 2026 |
| UNCY | EFFECT | bearish | 6/10 | Unicycive Therapeutics' universal shelf registration (S-3) was declared effective by the SEC on June 15, 2026, enabling | Jun 16, 2026 |
| NNVC | EFFECT | neutral | 3/10 | NanoViricides' resale registration statement (S-3) for 1,333,334 shares underlying warrants held by Orca Capital AG beca | Jun 16, 2026 |
| ALVO | PRESS-RELEASE | bearish | 6/10 | Alvotech priced a dilutive public offering of 22.7M shares at $3.75/share, expected to raise ~$85M, alongside a concurre | Jun 16, 2026 |
| ALVO | PRESS-RELEASE | bearish | 6/10 | Alvotech priced a dilutive public offering of 22.7M shares at $3.75/share, raising ~$85M in gross proceeds, with an addi | Jun 15, 2026 |
| ELVN | 144 | neutral | 2/10 | OrbiMed Capital LLC, acting as portfolio manager for The Biotech Growth Trust PLC, filed a Form 144 notice of intent to | Jun 15, 2026 |
| ELVN | 144 | bearish | 4/10 | OrbiMed Advisors LLC, a major healthcare investment firm and significant shareholder in Enliven Therapeutics, filed a Fo | Jun 15, 2026 |
| ELVN | 144 | neutral | 2/10 | OrbiMed Advisors LLC, on behalf of OrbiMed Genesis Master Fund, filed a Form 144 notice of intent to sell 9,086 shares o | Jun 15, 2026 |
| LGND | CLUSTER | neutral | 2/10 | Three directors sold a total of ~$1.95M in LGND shares over a 7-day window, representing only ~0.04% of the company's $5 | Jun 15, 2026 |
| CVKD | 144 | bearish | 5/10 | CEO Quang X. Pham filed a Form 144 on June 15, 2026, indicating intent to sell 40,000 shares of Cadrenal Therapeutics co | Jun 15, 2026 |
| PBYI | CLUSTER | neutral | 2/10 | Two directors at PUMA BIOTECHNOLOGY sold a combined $242K in open-market shares on June 12, 2026, representing just 0.06 | Jun 15, 2026 |
| ADTX | CLUSTER | bearish | 7/10 | Insider cluster at Aditxt shows 10% owners HRT Financial LP and Gong Sandie selling a combined 2.93M shares for ~$47K, w | Jun 15, 2026 |
| IPSC | CLUSTER | neutral | 2/10 | A cluster of insider transactions at Century Therapeutics shows a net selling direction, but the total value is only ~$5 | Jun 15, 2026 |
| IPSC | CLUSTER | neutral | 2/10 | Century Therapeutics insiders engaged in routine non-cash director grants (74,000 shares each to five directors) and min | Jun 15, 2026 |
| ABEO | CLUSTER | bearish | 5/10 | Five ABEO insiders, including the CEO and CFO, sold a total of $407K in open-market sales over a 7-day window. The clust | Jun 15, 2026 |
| ADPT | CLUSTER | neutral | 2/10 | Two C-suite insiders at Adaptive Biotechnologies sold a combined $790K in shares over a one-week window, representing ju | Jun 15, 2026 |
| ORKA | CLUSTER | neutral | 3/10 | Two ORKA insiders, a director and the SVP of Finance, sold $1.01M in open-market shares ($882K of that from director Car | Jun 15, 2026 |
| ORKA | CLUSTER | neutral | 2/10 | Four Oruka Therapeutics insiders (CEO, COO, General Counsel, and a Director) sold a total of ~$2.67M in open-market tran | Jun 15, 2026 |
| RARE | CLUSTER | neutral | 2/10 | Two insiders at Ultragenyx sold a combined $97K in open-market transactions on June 15, 2026. The EVP/Chief Legal Office | Jun 15, 2026 |